This CME activity will feature four HCV experts reviewing and discussing the most important studies presented on chronic hepatitis C during the 63rd AASLD. This review and discussion will provide unique insight into how knowledgeable experts review the key posters and presentations at the 63rd AASLD and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.
This activity will enable all participating clinicians and health care providers caring for HCV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.
This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the treatment and management of patients with HCV infection.
After completing this activity, participants should be able to:
Review clinically relevant posters and presentations on chronic hepatitis C made at the 63rd AASLD;
Explain to colleagues the clinical trials and data presented in the most important posters and presentations on chronic hepatitis C at the 63rd AASLD;
Explain the scientific integrity and clinical relevance of the most important posters and presentations on chronic hepatitis C at the 63rd AASLD;
Use the information and data presented in the most important posters and presentations at the 63rd AASLD to improve patient care.
Release Date: November 20, 2012
Expiration Date:
November 20, 2013
Estimated time to complete each Poster/Presentation: 15-30 minutes
Media: Internet
Douglas T. Dieterich, MD
Professor of Medicine and Director of CME
Department of Medicine
Director of Outpatient Hepatology
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York
Paul Y. Kwo, MD
Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana
Paul J. Pockros, MD
Head, Division of Gastroenterology/Hepatology
Director, SC Liver Research Consortium
The Scripps Clinic
La Jolla, California
Professor Jean-Michel Pawlotsky, MD, PhD
Director, National Reference Center for Viral Hepatitis B, C and Delta
Head, Department of Virology Henri Mondor Hospital
University of Paris-Est and INSERM U955
Creteil, France
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There will be 10 posters and presentations available for a total of 2.5 possible credit hours.
The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Dr. Douglas Dieterich:
Dr. Paul Kwo:
Dr. Paul Pockros:
Professor Jean-Michel Pawlotsky, MD, PhD
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following planners and managers, Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 |
High Rate of Sustained Virologic Response with the All-Oral Combination of Daclatasivir (NS5A Inhibitor) Plus Sofosbuvir (Nucleotide NS5B Inhibitor) with or without Ribavirin, in Treatment-naive Patients Chronically Infected with HCV Genotype 1, 2, or 3 |
 |
OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naive, genotype 1 HCV infected patients |
 |
Alisporivir plus Ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: Final results from VITAL-1 study |
 |
Once Daily Sofosbuvir (GS-7977) Plus Ribavirin in Patients with HCV Genotypes 1, 2, and 3: The ELECTRON Trial |
|
A 12-Week Interferon-free Treatment Regimen with ABT-450/r, ABT-267, ABT-333 and Ribavirin Achieves SVR12 Rates (Observed Data) of 99% in Treatment-Naïve Patients and 93% in Prior Null Responders with HCV Genotype1 Infection |
|
SVR in Chronic HCV GT-1 1-Infected Null Responders With Combination of Daclatasvir and Asunaprevir With or Without (PEG/RBV) and an Interferon-free, Ribavirin-free 12-Week Regimen of Daclatasvir, Asunaprevir, and BMS-791325 Yielded SVR4 of 94% in Treatment-Naïve Patients with GT-1 Chronic HCV Infection |
|
Safety and Efficacy of Telaprevir or Boceprevir in Combination with Peginterferon Alfa/Ribavirin, in 455 Cirrhotic Non Responders. Week 16 Analysis of the French Early Access Program (ANRS CO20-CUPIC) in Real-life Setting |
 |
Boceprevir (BOC) Combined with Peginterferon alfa-2b/ribavirin (P/RBV) in Treatment-Naïve Chronic HCV Genotype 1 Patients with Compensated Cirrhosis: Sustained Virologic Response (SVR) and Safety Subanalyses from the Anemia Management Study |
|
PILLAR and ASPIRE Trials, SOUND-C2 Study, MATTERHORN Study and Safety and SVR of MK-5172 for 12 Weeks with PEG-RBV for 24 Weeks in HCV GT-1 Treatment-Naive Noncirrhotic Patients |
|
Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results and Treatment of acute HCV infection in HIV co-infection: Influence of HCV genotype and ribavirin upon treatment outcome |
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Jointly Sponsored by the Postgraduate Institute for Medicine and ViralEd, Inc..
Supported by an educational grant from Merck & Co., Inc.
*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings
